Is COX-2 a perpetrator or a protector? Selective COX-2 inhibitors remain controversial

Acta Pharmacologica Sinica

Volumn 26, Issue 8, 2005, Pages 926-933

  Luo, Cheng ^a   He, Ming Liang ^b   Bohlin, Lars ^c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Cardiovascular disease; COX 2 inhibitor; Nonsteroidal anti inflammatory drug; Prostanoids

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CURCUMIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GINGER EXTRACT; LINOLEIC ACID; LUMIRACOXIB; MYRISTIC ACID; NATURAL PRODUCT; NONSTEROID ANTIINFLAMMATORY AGENT; OLEANOLIC ACID; PALMITIC ACID; PLANT EXTRACT; PLANTAGO EXTRACT; PROSTAGLANDIN E2; PROSTANOID; ROFECOXIB; THUNDER GOD VINE EXTRACT; UNCLASSIFIED DRUG; URSOLIC ACID; VALDECOXIB;

ANALGESIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPYRETIC ACTIVITY; ARTHRITIS; CARDIOTOXICITY; COMPUTER AIDED DESIGN; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFECT; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME KINETICS; ENZYME REGULATION; GASTRODUODENAL ULCER; GASTROINTESTINAL SYMPTOM; GINGER; HUMAN; INFLAMMATION; MEDICINAL PLANT; NEPHROTOXICITY; NOCICEPTION; PAIN; PLANTAGO; PROTEIN EXPRESSION; REVIEW; SPICE; STRUCTURE ACTIVITY RELATION; THUNDER GOD VINE;

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DRUG DESIGN; HUMANS; INFLAMMATION; MEMBRANE PROTEINS; MOLECULAR STRUCTURE; PAIN;

EID: 23844505961     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2005.00150.x     Document Type: Review

References (43)

1. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88: 692-6.
2. 2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990; 265: 16737-40.
3. Luo C, Laine JVO, Ylinen L, Teros T, Mäkinen M, Ristimäki A, et al. Expression of cyclooxygenase-2 in intestinal goblet cells of prediabetic non-obese diabetic mice. Acta Physiol Scand 2002; 174: 265-74.
4. Luo C, Trauss L, Treng T, Ristimäki A, Santti R. Constant exprkession of cyclooxygenase-2 gene in the lower urinary tract and prostate of the male rats treated with estrogen. Z Naturforsch 2001; 56C: 455-63.
5. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-dark MJ, Willoughby DA. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999; 5: 621-2.
6. Topol EJ. Arthritis Medicines and Cardiovascular Events: "House of Coxibs". J Am Med Assoc 2005; 293: 366-8.
7. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004; 18: 790-804.
8. Kraemer SA, Meade EA, DeWitt DL. Prostaglandin endoperoxide synthase gene structure: identification of the transcriptional start site and 5′-flanking regulatory sequences. Arch Biochem Biophys 1992; 293, 391-400.
9. Colville-Nash PR, Gilroy DW. Potential adverse effects of cyclooxygenase-2 inhibition: evidence from animal models of inflammation. BioDrugs 2001; 15: 1-9.
10. Onoe Y, Miyaura C, Kaminakayashiki T, Nagai Y, Noguchi K, Chen QR, et al. IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2- dependent prostaglandin synthesis in osteoblasts. J Immunol 1996; 156: 758-64.
11. Hinz B, Brune K, Pahl A. Cyclooxygenase-2 expression in lipopolysaccharide-stimulated human monocytes is modulated by cyclic AMP, prostaglandin E2 and non-steroidal anti-inflammatory drugs. Biochem Biophys Res Commun 2000; 278: 790-6.
12. Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3′- untranslated region. J Biol Chem 2000; 275: 11750-7.
13. Ristimäki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57: 1276-80.
14. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 1971; 231: 232-5.
15. Michiels JJ. Aspirin and platelet-lowering agents for the prevention of vascular complications in essential thrombocythemia. Clin Appl Thromb Hemost. 1999; 5: 247-51.
16. Lichtenstein DR, Wolfe MM. COX-2 selective NSAID, new and improved? J Am Med Assoc 2000; 284: 1297-9.
17. Luo C, Kallajoki M, Mäkinen M, Teros T, Ylinen L, Simell O. Distribution and contribution of cyclooxygenase (COX)-2 for diabetogenesis in NOD mouse model. Cell Tissue Res 2002; 310: 169-75.
18. McKanna JA, Zhang MZ, Wang JL, Cheng H, Harris RC. Constitutive expression of cyclooxygenase-2 in rat vas deferens. Am J Physiol. 1998; 275: R227-33.
19. Harris RC. Macula densa signaling, a potential role of cyclooxygenase-2 (COX-2)? Nephrol Dial Transplant 2000; 15: 1504-6.
20. Luo C, Laaja P. Inhibitors of JAKs/STATs and the kinases, a possible new cluster of drugs. Drug Discov Today 2004; 9: 268-75.
21. Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, et al. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 2002; 62: 3395-401.
22. Baba H, Kohno T, Moore KA and Woolf CJ. Direct activation of rat spinal dorsal horn neurons by prostaglandin E2. J Neurosci 2001; 21: 1750-6.
23. Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, et al. Interleukin-1b-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001; 410: 471-5.
24. Ma W, Eisenach JC. Morphological and pharmacological evidence for the role of peripheral prostaglandins in the pathogenesis of neuropathic pain. Eur J Neurosci 2002; 15: 1037-47.
25. Ellman MH, Curran J. Trial of tramadol/acetaminophen tablets for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug. J Rheumatol 2005; 32: 568-8.
26. Boutaud O, Aronoff DM, Richardson JH, Marnett LJ, Oates JA. Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H2 synthases. Proc Natl Acad Sci USA 2002; 99: 7130-5.
27. Bolting R, Ayoub SS. COX-3 and the mechanism of action of paracetamol/acetaminophen. Prostaglandins Leukot Essent Fatty Acids 2005; 72: 85-7.
28. van Ryn J, Trummlitz G, Pairet M. COX-2 selectivity and inflammatory processes. Curr Med Chem 2000; 7: 1145-61.
29. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1997; 385: 555-62.
30. Yang T, Endo Y, Huang YG, Smart A, Briggs JP, Schnermann J. Renin expression in COX-2-knockout mice on normal or low-salt diets. Am J Physiol Renal Physiol 2000; 279: F819-25.
31. Bonner JC, Rice AB, Ingram JL, Moomaw CR, Nyska A, Bradbury A, et al. Susceptibility of cyclooxygenase-2-deficient mice to pulmonary fibrogenesis. Am J Pathol 2002; 161: 459-70.
32. Mukherjee D, Topol EJ. COX-2: where are we in 2003? Cardiovascular risk and COX-2 inhibitors. Arthritis Res Ther 2003; 5: 8-11.
33. Adegboyega PA, Ololade O. Immunohistochemical expression of cyclooxygenase-2 in normal kidneys. Appl Immunohistochem Mol Morphol 2004; 12: 71-4.
34. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96: 272-7.
35. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289: 735-41.
36. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-80.
37. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102.
38. Perera P, Ringbom T, Huss U, Vasänge M., Bohlin L. Search for natural products with effect on cyclooxygenase-2. In: Tringali C, editor. Bioactive Compounds from Natural Sources. London: Taylor & Francis; 2001. p433-72.
39. Subbaramaiah K, Michaluart P, Chung WJ, Tanabe T, Telang N, Dannenberg AJ. Resveratrol inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Ann NY Acad Sci 1999; 889: 214-23.
40. Ringbom T, Huss U, Stenholm A, Flock S, Skattebol L, Perera P, et al. COX-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod 2001; 64: 745-9.
41. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 2005; 201: 713-22.
42. Ringbom T, Segura L, Noreen Y, Perera P, Bohlin L. Ursolic acid from Plantago major, a selective inhibitor of cyclooxygenase-2 catalyzed prostaglandin biosynthesis. J Nat Prod 1998; 61: 1212-5.
43. 2 EP1 receptor mediates pain perception and regulates blood pressure. J Clin Invest 2001; 107: 325-31.